"I am watching the trend and if the short interest increase, we will know that we just past the bottom. If it is 6M it will be awesome, but not very probable."
You are probably correct about the 6M target, How did you get there?
We have been going down around 1M in each reporting interval recently and all of a sudden you are looking for a 5M drop?
I believe next report will see us at around 9M judging by the volume in December.
Sentiment: Strong Buy
Adult Obesity Facts 2014(surely 35% of Americans are not diabetics)
More than one-third (34.9% or 78.6 million) of U.S. adults are obese. [Read abstract Journal of American Medicine (JAMA)External Web Site Icon]
Obesity-related conditions include heart disease, stroke, type 2 diabetes and certain types of cancer, some of the leading causes of preventable death. [Read guidelinesExternal Web Site Icon]
The estimated annual medical cost of obesity in the U.S. was $147 billion in 2008 U.S. dollars; the medical costs for people who are obese were $1,429 higher than those of normal weight.
INO 9,11 Dec 24
ATRS 2.65 Dec24
It is interesting to see that no one that has voted so far has picked ATRS, makes you wonder why they are still on this board if their pick's are going to outperform ATRS. Sell and buy your pick's instead you obviously believe there is more money to be made in those stocks.
The three weeks before 11/28 the price per script was 735 every week for some reason.
The difference in average price per script/prescription is because varying amounts of Otrexup packs per refill. One refill for one month and another for three months etc. They are all payed for when they go out the door.
The U.S. health regulator approved a formulation of Novo Nordisk's diabetes drug, liraglutide, for treating patients of obesity, a disease that affects one in three Americans.
The injectable drug, to be marketed as Saxenda, is the second obesity treatment to be approved this year after Orexigen Therapeutics Inc's oral medication Contrave in September.
Saxenda enters a market that is yet to realize its potential due to limited effectiveness of existing drugs, reimbursement hurdles, bungled launches and the perception of obesity as a 'lifestyle' disease.
The drug has been approved for patients with a body mass index of 30 or above and at least one weight-related health condition such as diabetes, the U.S. Food and Drug Administration said on Tuesday.
A lower dose of liraglutide, marketed as Victoza, was approved for use in diabetes patients in 2010.
Novo believes Saxenda has blockbuster potential, although doctors doubt it will be a game changer.
"None of the available drugs and none ... on the horizon are sufficiently powerful to eradicate obesity," Lee Kaplan, chair of the clinical committee of the Obesity Society, told Reuters in October.
Saxenda's rivals include Vivus Inc's Qsymia and Arena Pharmaceuticals Inc's Belviq, which are taken orally.
A study showed that half the patients given Saxenda lost at least 5 percent body weight, the FDA said. Rival drugs show 2-5 percent weight loss over and above diet and exercise.
andre....Or this version
Reading the responses to the post from whogo, where he asked a reasonable question, prompts me to copy and paste some part of this article. It is funny, sarcastic but very true.
2. When spending time on the message board, be sure to read closely all posts from those who are the most vocal opponents of the biotech stock you own. These people demonstrate their commitment by never writing anything positive. The best posters will write at length about how overvalued is your stock. Lucky for you the world does not know this yet; you are one of a select few! Take the opportunity to sell now. You may safely ignore others who are more positive. It is well known these pumpers are paid by hedge funds and are only hanging out on the message board to boost your confidence.
3. Sometimes you will come across information about your biotech stock which conflicts with your beliefs. When this happens, it's best to either ignore the positive information, or better yet, copy/post to the Internet stock message board with a healthy serving of disgust and ridicule. If you're lucky, the resident expert on the message board will help remind everyone the positive information about the biotech stock was obviously the work of an uninformed person, a paid pumper. It's much better to learn all you need to know about the science of your biotech stock from other un-educated true dis-believers on Internet stock message boards. Less
If you respect and read whogos posts you should know that whogo does not own one single share of ATRS, I think he sold out at 2,26 and immediately changed his posts from positive to negative. It's as sure as the seasons they all change for the same reason(almost whogo's post changes depending on if he is in or out).
gand, What Hobbs said(that probably referred to Teva)was that one product in the pipeline had already been approved and had recieved the letter from FDA but not yet announced it publicly. The undisclosed new partner I think he said is still undisclosed.
Why would they compare Otrexup with oral MTX,. I don't understand please explain for a layman.
Injector with adjustable dosing US 20090299278 A1
An injector for injecting medicament in a patient. The injector includes a container comprising a fluid chamber containing a first volume of a medicament, and an injection conduit associated with the fluid chamber for defining a fluid pathway therefrom to inject the medicament from the fluid chamber through the injection conduit to an injection location. The injector also includes a firing mechanism associated with the fluid chamber for expelling the medicament from the fluid chamber through the injection conduit, and a volume-control mechanism operable to control a fraction of the first volume of medicament that is injected when the firing mechanism is actuated to inject the medicament.
Citing Patent----------Filing date------Publication date Applicant Title
US8496619 ----------Jul 15, 2011----Jul 30, 2013 Antares Pharma, Inc.
WO2013012745A1- Jul 13, 2012----Jan 24, 2013 Antares Pharma, Inc.
WO2013169800A1- May 7, 2013----Nov 14, 2013 Antares Pharma, Inc.
WO2013169804A1- May 7, 2013----Nov 14, 2013 Antares Pharma, Inc.
Cited by examiner
I don't thats why I was asking about the update. Aintno, I cant find the schedule on NASDAQ were did you find it? Interestsing to see thee effort to bring our price down at the moment..I don't think it will work, the people accumulating are picking up the scraps as soon as they are handed out. MERRY CHRISTMAS Everyone!
You and your wild speculations, Merry Christmas again :o)